EIKN

Business Context and Reporting Period

Company: Eikon Therapeutics, Inc. (EIKN)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Eikon is a late-stage clinical biopharmaceutical company focused on oncology. It utilizes a proprietary Single Molecule Tracking (SMT) technology platform to discover and develop novel therapies. The company has no approved products and has not generated revenue from product sales. Its pipeline includes EIK1001 (TLR 7/8 dual-agonist), EIK1003 and EIK1004 (selective PARP1 inhibitors), EIK1005 (WRN helicase inhibitor), and EIK1006 (AR antagonist).

Key Financial Metrics

Note: The company reported no debt outstanding as of December 31, 2025.

Material Changes vs. Prior Period

• Increased Net Loss: Net loss increased by 33% to $324.2 million in 2025, driven by higher operating expenses.
• R&D Expense Growth: R&D expenses rose 22% to $250.3 million, primarily due to increased clinical trial activity ($47.7 million increase) and facility costs following the move to a new headquarters in Millbrae, California.
• G&A Expense Surge: G&A expenses increased 59% to $88.6 million. This was largely due to non-cash impairments of $21.3 million related to vacated properties in Hayward, CA, and New York, NY, as well as stock-based compensation adjustments from option repricing.
• Capital Raise: In February 2025, the company raised approximately $350.7 million in a Series D preferred stock financing. Subsequently, in February 2026 (post-period), the company completed an Initial Public Offering (IPO) raising approximately $349.0 million in net proceeds.

Guidance, Outlook, and Risks

Outlook and Liquidity: Management estimates that existing cash resources, including IPO proceeds, will fund operations into the second half of 2027. The company expects to continue incurring substantial losses as it advances clinical trials and expands infrastructure.

Clinical Milestones:

• EIK1001: Global Phase 2/3 registrational trial in advanced melanoma is ongoing; first interim analysis expected in H2 2026. Phase 2/3 site selection for NSCLC initiated.
• EIK1003/EIK1004: Phase 1/2 dose escalation ongoing; data readouts expected in H2 2026.
• EIK1005: Phase 1/2 trial dosing initiated; data expected H1 2027.

Material Risks and Contingencies:

• Internal Control Weakness: The company identified a material weakness in internal controls over financial reporting related to complex lease accounting, resulting in a restatement of Q3 2025 financials. Remediation is underway.
• Capital Requirements: The company requires substantial additional capital to fund operations. Failure to raise capital could force delays or elimination of development programs.
• Collaboration Disputes: A payment-related dispute exists with licensor Seven and Eight Biotherapeutics Corp., which could require arbitration.
• Regulatory and Clinical Risk: No products are approved; success depends entirely on clinical trial outcomes and regulatory approvals, which are uncertain.

Key Facts for Investor Verification

• Restatement Impact: Verify the specific adjustments made to the Q3 2025 balance sheet and cash flow statement due to the material weakness in lease accounting.
• Seven and Eight Dispute: Monitor the status of the payment dispute with Seven and Eight Biotherapeutics Corp. and potential arbitration outcomes.
• Lease Obligations: Review the $562.0 million in non-cancellable lease obligations, with $41.4 million due in 2026, to assess future cash commitments.
• Upcoming Milestones: Track the timing and results of the EIK1001 interim analysis (H2 2026) and EIK1003/1004 data readouts (H2 2026), as these are critical value drivers.
• Patent Status: Note that while EIK1001 has issued patents, EIK1003, EIK1004, EIK1005, and EIK1006 currently rely on pending patent applications with no issued patents as of the filing date.